Terence M Williams MD, PhD
Terence M Williams MD, PhD
094E James Cancer Hospital 300 W 10th Avenue Columbus OH 43210
- Molecular Biology and Cancer Genetics
General Research InterestExploring novel mechanisms of chemo- and radiosensitization in a variety of malignancies, as well as DNA damage response pathways in tumors and how this relates to therapeutic resistance. Other areas of interest include the role of stroma and tumor-microenvironment, and identifying molecular signatures which predict metastasis and response to radiation and molecularly-targeted therapies.
Research DescriptionMy laboratory research interests center around gastrointestinal (GI) malignancies, including pancreatic cancer. I am interested in the molecular biology and genetics of DNA damage response, and those pathways which dictate tumor aggressiveness such as invasion and metastasis, and those factors governing response to treatment from chemotherapy, molecularly-targeted agents, and radiation. I am also interested in the role of pancreatic stromal elements and their relationship to tumorigenesis, metastasis, and resistance to therapy. In addition, I have a strong interest in better understanding the role of Caveolin-1 (Cav-1) in aggressive neoplasms, such as pancreatic ductal carcinoma, glioblastoma, and renal cell carcinoma, which are neoplasms demonstrating a high degree of Cav-1 overexpression.
Ru P, Williams TM, Chakravarti A, Guo DTumor metabolism of malignant gliomas.Cancers (Basel) 5(4) 1469-84 11/8/2013
Williams TM, Nyati S, Ross BD, Rehemtulla AMolecular imaging of the ATM kinase activity.Int J Radiat Oncol Biol Phys 86(5) 969-77 8/1/2013
Williams TM, Maier ARole of stereotactic body radiation therapy and proton/carbon nuclei therapies.Cancer J 19(3) 272-81 5/1/2013
Williams TM, Galbán S, Li F, Heist KA, Galbán CJ, Lawrence TS, Holland EC, Thomae TL, Chenevert TL, Rehemtulla A, Ross BDDW-MRI as a Predictive Biomarker of Radiosensitization of GBM through Targeted Inhibition of Checkpoint Kinases.Transl Oncol 6(2) 133-42 4/1/2013
Williams TM, Flecha AR, Keller P, Ram A, Karnak D, Galban S, Galban CJ, Ross BD, Lawrence TS, Rehemtulla A, Sebolt-Leopold JCotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer.Mol Cancer Ther 11(5) 1193-202 5/1/2012
Galbán S, Lemasson B, Williams TM, Li F, Heist KA, Johnson TD, Leopold JS, Chenevert TL, Lawrence TS, Rehemtulla A, Mikkelsen T, Holland EC, Galbán CJ, Ross BDDW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.PLoS One 7(4) e35857 1/1/2012
© The Ohio State University